tbuckley/cabot-search huggingface dataset:
Abstract 17175: Appropriate Selection Criteria Whether Intracardiac or Transesophageal Echocardiography Should be Used for Image Guidance During Transcatheter Atrial Septal Defect Closure Without General Anesthesia
Authors: Michiyo Yamano, Tetsuhiro Yamano, Takeshi Nakamura, Naohiko Nakanishi, Kan Zen, Hirokazu Shiraishi, Takeshi Shirayama, Satoaki Matoba
Journal: Circulation (2016)

Introduction: Standard transcatheter atrial septal defect (ASD) closure is performed under the guidance of transesophageal echocardiography (TEE) and general anesthesia (GA). However, for adults; e...
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
Authors: Matthew T. Chang, Alexander Penson, Neil B. Desai, Nicholas D. Socci, Ronglai Shen, Venkatraman E. Seshan, Ritika Kundra, Adam Abeshouse, Agnes Viale, Eugene K. Cha, Xueli Hao, Victor E. Reuter, Charles M. Rudin, Bernard H. Bochner, Jonathan E. Rosenberg, Dean F. Bajorin, Nikolaus Schultz, Michael F. Berger, Gopa Iyer, David B. Solit, Hikmat A. Al-Ahmadie, Barry S. Taylor
Journal: Clinical Cancer Research (2017)

Small-cell carcinoma of the bladder (SCCB) is a rare and aggressive neuroendocrine tumor with a dismal prognosis and limited treatment options. As SCCB is histologically indistinguishable from small-cell lung cancer, a shared pathogenesis and cell of origin has been proposed. The aim of this study is to determine whether SCCBs arise from a preexisting urothelial carcinoma or share a molecular pathogenesis in common with small-cell lung cancer.
Academic Promotion at a Medical School
Authors: M L Batshaw, L P Plotnick, B G Petty, P K Woolf, E D Mellits
Journal: New England Journal of Medicine (1988)

We studied promotions at Johns Hopkins University School of Medicine to determine whether clinician-teachers are less likely to be promoted or are promoted later in life than researchers and whether those who are promoted have more articles published than those who are not promoted. Over a five-year period, 93 percent of candidates for the rank of associate professor and 79 percent of the candidates for the rank of professor were promoted. There were no significant differences between clinical and research faculty members in terms of the probability that they would be promoted or their age at promotion to either associate professor or professor. Despite these findings, the responses to a questionnaire indicated that former faculty members perceived clinician-teachers as less likely than researchers to be promoted. Those who were promoted had had about twice as many articles published in peer-reviewed journals as those who were not promoted. We recommend improved counseling of medical school faculty members and more extensive discussion of the criteria for promotion and the chances of academic success.
Reply to Cooper <i>et al.</i>: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease
Authors: Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix J. F. Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, Jadwiga A. Wedzicha
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Meox1 accelerates myocardial hypertrophic decompensation through Gata4
Authors: Dan Lu, Jizheng Wang, Jing Li, Feifei Guan, Xu Zhang, Wei Dong, Ning Liu, Shan Gao, Lianfeng Zhang
Journal: Cardiovascular Research (2017)

Abstract Aims Pathological hypertrophy is the result of gene network regulation, which ultimately leads to adverse cardiac remodelling and heart failure (HF) and is accompanied by the reactivation of a ‘foetal gene programme’. The Mesenchyme homeobox 1 (Meox1) gene is one of the foetal programme genes. Meox1 may play a role in embryonic development, but its regulation of pathological hypertrophy is not known. Therefore, this study investigated the effect of Meox1 on pathological hypertrophy, including familial and pressure overload-induced hypertrophy, and its potential mechanism of action. Methods and results Meox1 expression was markedly down-regulated in the wild-type adult mouse heart with age, and expression was up-regulated in heart tissues from familial dilated cardiomyopathy (FDCM) mice of the cTnTR141W strain, familial hypertrophic cardiomyopathy (FHCM) mice of the cTnTR92Q strain, pressure overload-induced HF mice, and hypertrophic cardiomyopathy (HCM) patients. Echocardiography, histopathology, and hypertrophic molecular markers consistently demonstrated that Meox1 overexpression exacerbated the phenotypes in FHCM and in mice with thoracic aorta constriction (TAC), and that Meox1 knockdown improved the pathological changes. Gata4 was identified as a potential downstream target of Meox1 using digital gene expression (DGE) profiling, real-time PCR, and bioinformatics analysis. Promoter activity data and chromatin immunoprecipitation (ChIP) and Gata4 knockdown analyses indicated that Meox1 acted via activation of Gata4 transcription. Conclusion Meox1 accelerated decompensation via the downstream target Gata4, at least in part directly. Meox1 and other foetal programme genes form a highly interconnected network, which offers multiple therapeutic entry points to dampen the aberrant expression of foetal genes and pathological hypertrophy.
Medical Specialty Board Finances—Reply
Authors: Brian C. Drolet, Vickram J. Tandon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Don't forget the neurobiology: An experimental approach to linguistic representation
Authors: Peter Hagoort
Journal: Behavioral and Brain Sciences (2017)

Acceptability judgments are no longer acceptable as the holy grail for testing the nature of linguistic representations. Experimental and quantitative methods should be used to test theoretical claims in psycholinguistics. These methods should include not only behavior, but also the more recent possibilities to probe the neural codes for language-relevant representations.
Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases.
Authors: Bassel F. El-Rayes, Walid Labib Shaib, Roger S.H. Williams, Zhengjia Chen, P Nagaraju Ganji, Edith Brutcher, Hyun Sik Kim
Journal: Journal of Clinical Oncology (2015)

4092 Background: Pasireotide (P) is a somatostatin (SST) analogue active against receptors 1, 2, 3, and 5. Everolimus (E) is an mTOR inhibitor. mTOR and SST pathways activate angiogensis, survival and increase radio-resistance. Methods: Major eligibility criteria: unresectable bilobar liver metastasis from low or intermediate grade NET, prior therapy with octreotide LAR 30mg, evidence of disease progression by RECIST 1.1, hemoglobin A1C less than 7, and adequate liver functions. A 3+3 dose escalation design was used. Everolimus dose levels were 2.5 mg, 5 mg, and 10 mg every day. Standard dosing and administration was used for Sir-sphere(R). E and P (600mcg BID) were given 1 week prior to SIRT and until 29 days after second SIRT when E (10mg daily) and P LAR (60 mg q 28days) were started. Dose limiting toxicities (DLT) were defined as the occurrence of any treatment related grade 4 hematologic or grade 3 non-hematologic toxicities lasting more than 7 days or grade 4 non-hematologic toxicity. Serum pharmacodynamic markers (VEGF, FGF, PIGF, Il-8, IGF-1, IGF-2, IGF binding proteins) were collected at baseline, prior to and 24 hours after first SIRT. QOL patients were assessed monthly by the Norfolk QOL-NET questionnaire. Results: 13 patients (pts) were enrolled in the study. 1 pt was in-evaluable for toxicity. Pt characteristics were median age 61 yrs, 7 males, primary site (midgut 4 pts, pancreas 3, lung 2, unknown 2, gastric 1, colon 1), and low grade (11). 3 pts had liver only disease. No DLT was observed. The grade 3 toxicities throughout the study were: hyperglycemia (6 pts) and thrombocytopenia (2pts). Liver toxicities observed in the first 28 days were bilirubin grade 1 (1 pt), bilirubin grade 2 (1 pt), and AST/ALT elevation grade 1 (8 pts). Best response was PR (6 pts), SD (3 pts), PD (3 pts- 2 had extrahepatic progression). 6 pts (50%) are still with no progression and median PFS is 9 months (95%CI 4-21). Conclusions: The RP2D is everolimus 10 mg QD and pasireotide 600 mcg BID. P, E and SIRT was well tolerated with minimal liver toxicity. The preliminary results for activity appear promising and control of liver disease is excellent with only 1 pt (8%) having progressive disease in the liver. Clinical trial information: NCT01469572.
Viagra will be available over counter
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

British men aged over 18 will be able to buy sildenafil (Viagra Connect, containing 50 mg sildenafil) over the counter, after the Medicines and Healthcare Products Regulatory Agency (MHRA) reclassified the drug from prescription-only.

The agency said that the move will help more men with erectile dysfunction to access treatment without using illegal online sites to purchase the drug. Over the past five years investigators from MHRA have seized more than £50m …
Starch based nanofibrous scaffolds for wound healing applications
Authors: Vijaya Sadashiv Waghmare, Pallavi Ravindra Wadke, Sathish Dyawanapelly, Aparna Deshpande, Ratnesh Jain, Prajakta Dandekar
Journal: Bioactive Materials (2017)

Starch is an attractive polymer for wound healing applications because of its wide availability, low cost, biocompatibility, biodegradability and wound-healing property. Here, we have fabricated starch-based nanofibrous scaffolds by electrospinning for wound healing applications. The diameter of the optimized nanofibers was determined by field emission scanning electron microscopy (FE-SEM) and was found to be in the range of 110–300 nm. The mechanical strength (0.5–0.8 MPa) of the nanofibrous scaffolds was attuned using polyvinyl alcohol (plasticizer) and glutaraldehyde (crosslinking agent), to impart them with sufficient durability for skin tissue engineering. Absence of negative interactions between the polymers was confirmed by Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR), differential scanning microscopy (DSC) and thermal gravimetric analysis (TGA). Cellular assays with L929 mouse fibroblast cells indicated the ability of the scaffolds to promote cellular proliferation, without exhibiting any toxic effect to the cells. Thus, the nanofibrous scaffolds demonstrated potential for wound healing applications.
Traumatic Brain Injury and Cases of Abnormal Menstrual Pattern
Authors: Salvatore Benvenga, Alessandro Sindoni, Fausto Fama
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Advances in cardiology, vol 25: Edited by J T August, M W Anders, and F Murad. (Pp 464; $110.) San Diego: Academic Press, 1994. ISBN 0-12-032925-5
Authors: K. Banner
Journal: Cardiovascular Research (1995)

Journal Article Advances in cardiology, vol 25: Edited by J T August, M W Anders, and F Murad. (Pp 464; $110.) San Diego: Academic Press, 1994. ISBN 0-12-032925-5 Get access Advances in cardiology, vol 25. Edited by August J T Anders M W Murad F. (Pp 464; $110.) San Diego: Academic Press, 1994. ISBN 0-12-032925-5. KH Banner KH Banner London, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 5, May 1995, Page 728, https://doi.org/10.1016/S0008-6363(95)90138-8 Published: 01 May 1995
FOLLICULAR HELPER T-CELLS POPULATE THE INTRAHEPATIC INFILTRATES OF HCV GENOTYPE-1 CHRONICALLY INFECTED PATIENTS AND PREDICT THE ACHIEVEMENT OF VIROLOGICAL RESPONSE FOLLOWING IFN-BASED TREATMENT
Authors: C. Tripodo, S. Petta, D. Cabibi, C. Camma, C. Guarnotta, M. Colombo, D. Ferraro, A. Craxi
Journal: Hepatology (2010)
The role of plasma epidermal growth factor receptor mutations test in non-small cell lung cancer
Authors: P.T. Thang, T.B. Thu, H.T. Toan, T.T. Tung, P.V. Loi, V.T. My, T.A. Le, L.T.T. Suong, L.T. Vu, N.T. Hang, N.T. Son
Journal: Annals of Oncology (2017)
Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy
Authors: Thibaud Damy, Stefano Ghio, Alan S. Rigby, Luc Hittinger, Sandra Jacobs, Francisco Leyva, Juan F. Delgado, Jean-Claude Daubert, Daniel Gras, Luigi Tavazzi, John G.F. Cleland
Journal: Journal of the American College of Cardiology (2013)
Overall Survival vs Disease-Specific Survival—Reply
Authors: Sham Mailankody, Vinay Prasad
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Hereditary Hemorrhagic Telangiectasia
Authors: Alan E. Guttmacher, Douglas A. Marchuk, Robert I. White
Journal: New England Journal of Medicine (1995)

Identified nearly a century ago, hereditary hemorrhagic telangiectasia, or Rendu–Osler–Weber syndrome, has long been viewed as a rare condition producing minor discomfort for affected persons. However, this disorder is now considered to be more common than previously thought,15 and the associated brain and pulmonary lesions are sources of substantial morbidity and mortality.3,68 Wider recognition of the condition and awareness of its sequelae can help avoid the considerable risks associated with its mismanagement. Advances in molecular genetics have demonstrated that hereditary hemorrhagic telangiectasia is actually a group of autosomal dominant disorders.913 The recent identification of the gene . . .
CHOREA AND RHEUMATISM.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adapting clinical guidelines in India—a pragmatic approach
Authors: Abha Mehndiratta, Sangeeta Sharma, Nikhil Prakash Gupta, Mari Jeeva Sankar, Francoise Cluzeau
Journal: BMJ (2017)

Adapting international guidelines to suit local context can drive evidence based practice in low and middle income countries, say <b>Abha Mehndiratta and colleagues</b>, as they describe a pragmatic approach to develop standard treatment guidelines for India
Encuesta europea sobre las politicas vacunales del BCG y vigilancia en los niños, 2005
Authors: A Infuso, D Falzon
Journal: Eurosurveillance (2006)

En 2005, los 25 paises de la Union Europea (UE), asi como Andorra, Bulgaria, Noruega, Rumania y Suiza participaron en una encuesta sobre la vacunacion por BCG en los ninos. En 12 paises, se recomendaba BCG para todos ninos de menos de 12 meses, y en cinco paises en ninos mayores. Diez paises recomiendan la vacunacion en ninos a riesgo (definido por su origen, los contactos o los viajes), siete paises no vacunan sistematicamente con BCG y cuatro practican la revacunacion. En los paises con vacunacion universal por el BCG, la cobertura vacunal era alta (83,0% a 99,8%). Se identificaron con frecuencia casos de tuberculosis en ninos vacunados (entre 30% y 98% en cinco paises que tenian una politica vacunal universal o centrada en grupos de alto riesgo). Recientemente, fueron notificadas pocas infecciones debidas al BGC (0-1/100 000 vacunados). Las recomendaciones sobre el BCG son muy diferentes entre paises y casi la mitad de los paises participantes en la encuesta han previsto modificaciones, al mismo tiempo en el que el Centro europeo para la prevencion y control de las enfermedades (ECDC) esta recomendando la armonizacion de las estrategias vacunales. Son importantes los datos sobre cobertura vacunal del BCG en los grupos diana, pero su disponibilidad en Europa es escasa. La informacion sobre el estatus vacunal y la inclusion en grupos de riesgo deberian ser recogidas de forma rutinaria por medio de las notificaciones de casos de tuberculosis. Tambien seria necesario estudiar la incidencia de los efectos adversos graves del BCG en ninos. Puesto que la eficacia de la revacunacion no es evidente, esta deberia ser interrumpida.
Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study
Authors: Ettore Di Trapani, Alessandro Nini, Irene Locatelli, Roberta Buono, Andrea Russo, Paolo Dell’Oglio, Fabio Castiglione, Giovanni La Croce, Fabio Benigni, Francesco Montorsi, Andrea Salonia, Ilaria Cavarretta, Alberto Briganti
Journal: European Urology (2017)
Risk of suicide in persons with gastrointestinal cancer: A population-based study.
Authors: Aileen Deng, Atrayee Basu Mallick
Journal: Journal of Clinical Oncology (2017)

197 Background: Patients with cancer have nearly twice the incidence of suicide compared to the general population(1). To date, identifying patients at risk for suicide remains challenging. The purpose of this study was to identify risk factors of suicide among patients with GI cancer. Methods: A retrospective analysis was completed using Surveillance, Epidemiology, and End Results data from 1973 to 2014. Comparisons with the general US population were based on US mortality data collected by the National Center for Health Statistics. Suicide incidence, rates and standardized mortality ratio (SMR) were obtained by SEER*Stat 8.3.4. Results: Among 711859 patients with GI cancer observed for 3373014 person-years, 1116 suicides were identified, for an adjusted suicide rate of 33.1/100,000 person-years (SMR 1.74 [95% CI 1.64-1.85]). The highest suicide risks (SR) were in esophageal (SMR 5.42 [95% CI 4.30-6.75]), pancreatic (SMR 4.91 [95% CI 3.83-6.19]) and liver or intrahepatic biliary cancer (SMR 3.36 [95% CI 2.35-4.65]). Higher SRs were associated with unmarried status, age 40 years and older at diagnosis and the first 5 years after diagnosis. In esophageal (EC) and pancreatic (PC) cancer, SR was 8 folds higher in unmarried patients compared to the general population with a SMR of 8.31 [95% CI 5.68-11.73] and 7.68 [95% CI 5.18-10.97], respectively. In EC and PC, SR was highest in patients &gt; 80 years (SMR 7.09 [95% CI 3.40-13.03]) and 40-59 years at diagnosis (SMR 7.10 [95% CI 1.93-18.18]), respectively. Patients have especially high SR the first year after diagnosis in EC (SMR 10.25 [95% CI 7.65-13.44]) and PC (SMR 7.72 [95% CI 5.83-10.03]). Conclusions: While overall, patients with GI cancer have nearly twice the SR, those with certain cancer subtypes have up to 5 times the SR when compared to the general population. SRs are highest in esophageal, pancreatic and liver or intrahepatic biliary cancer. Suicide screening should especially target patients with EC and PC who are unmarried or lack a support system and within the first year after cancer diagnosis.